Project Hunt: On-chain Prediction Gaming Platform MetaWin Is the Most Unfollowed Project by Top Figures in the Past 7 Days
2025/06/26 09:12According to ChainCatcher, data tracked by the Web3 asset data platform RootData X shows that in the past seven days, the on-chain prediction gaming platform MetaWin has attracted the most new followers among X (Twitter) top influencers. Notable new followers of this project include crypto trader James Wynn (@JamesWynnReal), crypto trader James Wynn (@JamesWynnReal), and zac.eth (@zacxbt).
In addition, the projects that saw the most unfollows from X top influencers include Cosmos, Premia, DEXTools, and Symbiosis Finance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom
The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.
SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”
SQM.US still reports seeing "encouraging" potential demand trends.
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.
According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years
Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.
